C-reactive protein to identify early risk for development of calcific aortic stenosis: right marker? Wrong time?

Calcific aortic valve disease is the most common acquired valvular disorder in developed countries. Disease involvement of the trileaflet aortic valve spans the spectrum from “aortic sclerosis,” characterized by valve thickening, fibrosis, and microscopic calcification without left ventricular

[1]  R. Levy,et al.  Identification and characterization of calcifying valve cells from human and canine aortic valves. , 1999, The Journal of heart valve disease.

[2]  M. Budoff,et al.  Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. , 2005, Archives of internal medicine.

[3]  R. Bonow,et al.  Atorvastatin Inhibits Hypercholesterolemia-Induced Cellular Proliferation and Bone Matrix Production in the Rabbit Aortic Valve , 2002, Circulation.

[4]  S. Hagl,et al.  Receptor activator of nuclear factor κB ligand and osteoprotegerin regulate aortic valve calcification , 2004 .

[5]  B. Lüderitz,et al.  Tissue resident C reactive protein in degenerative aortic valves: correlation with serum C reactive protein concentrations and modification by statins , 2005, Heart.

[6]  D. Newby,et al.  Emerging medical treatments for aortic stenosis: statins, angiotensin converting enzyme inhibitors, or both? , 2005, Heart.

[7]  R. Prescott,et al.  A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. , 2005, The New England journal of medicine.

[8]  Rosario V. Freeman,et al.  Spectrum of Calcific Aortic Valve Disease: Pathogenesis, Disease Progression, and Treatment Strategies , 2005, Circulation.

[9]  H. White,et al.  Effect of aortic valve replacement on c-reactive protein in nonrheumatic aortic stenosis. , 2003, The American journal of cardiology.

[10]  A. Gown,et al.  Characterization of the Early Lesion of ‘Degenerative’ Valvular Aortic Stenosis: Histological and Immunohistochemical Studies , 1994, Circulation.

[11]  A. Khera,et al.  Relationship Between C-Reactive Protein and Subclinical Atherosclerosis: The Dallas Heart Study , 2005, Circulation.

[12]  Y. Soini,et al.  Progression of human aortic valve stenosis is associated with tenascin-C expression. , 2002, Journal of the American College of Cardiology.

[13]  S. Achenbach,et al.  Progression of Aortic Valve Calcification: Association with Coronary Progression of Aortic Valve Calcification Association with Coronary Atherosclerosis and Cardiovascular Risk Factors , 2022 .

[14]  A. Pietroiusti,et al.  C-reactive protein is increased in patients with degenerative aortic valvular stenosis. , 2001, Journal of the American College of Cardiology.

[15]  Sridevi Devaraj,et al.  Demonstration That C-Reactive Protein Decreases eNOS Expression and Bioactivity in Human Aortic Endothelial Cells , 2002, Circulation.

[16]  J. Zamorano,et al.  Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. , 2007, Journal of the American College of Cardiology.

[17]  J. Thyberg,et al.  Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[18]  M. Mäyränpää,et al.  Induction of local angiotensin II-producing systems in stenotic aortic valves. , 2004, Journal of the American College of Cardiology.

[19]  N. Rifai,et al.  Inflammatory markers in men with angiographically documented coronary heart disease. , 1999, Clinical chemistry.

[20]  F. Ohme,et al.  The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis , 2001, Heart.

[21]  Catherine M. Otto,et al.  Clinical Factors Associated With Calcific Aortic Valve Disease , 1997 .

[22]  K. O’Brien.  Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[23]  M. Schemper,et al.  Statins but Not Angiotensin-Converting Enzyme Inhibitors Delay Progression of Aortic Stenosis , 2004, Circulation.

[24]  C. Otto.  Why is aortic sclerosis associated with adverse clinical outcomes? , 2004, Journal of the American College of Cardiology.

[25]  B. Psaty,et al.  Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study. , 2007, Journal of the American College of Cardiology.

[26]  P. Ridker.  Clinical application of C-reactive protein for cardiovascular disease detection and prevention. , 2003, Circulation.